New German Data Show the Use of Endocuff Vision® May Improve Adenoma Detection Rates and Reduce Health System Costs

ENDOCUFF VISION® may lead to an overall saving in colorectal cancer treatment costs of over €5 million

London, Wednesday 11 November 2015, 07:00 GMT: Norgine B.V. today announced new data showing that ENDOCUFF VISION®, a colonoscope device, when used with a 2L polyethylene glycol + ascorbate components bowel preparation, may improve the adenoma detection rate (ADR), which may reduce the development of colorectal cancer, avoid treatment costs and reduce mortality. These data were presented at the ISPOR Annual Congress 2015.1

The model, that uses a cohort of 10,000 German patients eligible for screening, demonstrates that use of the device with a 2L polyethylene glycol + ascorbate components bowel preparation can help to improve the ADR compared to the use of bowel preparation alone. This increased ADR can help avoid progression to colorectal cancer in more patients. Furthermore, the model shows that despite an increase in the overall cost due to repeat colonoscopies, use of the device leads to a saving in colorectal cancer treatment costs of €283 per person screened over 10 years, resulting in an overall saving of over €5 million.

ENDOCUFF VISION® is a device attached at the end of the colonoscope that opens up the field of view by retracting folds during withdrawal.

Peter Martin, Chief Operating Officer at Norgine said: “We know that the detection and removal of adenomas during colonoscopy substantially reduces both the development of and death from colorectal cancer. Today’s data are an important milestone that further underscores the vital role that ENDOCUFF VISION® can play for patients and health systems by significantly improving detection of tumors.”

Colorectal cancer is the second most common cancer in Europe, with 412,00 new diagnoses every year.2,3 The prevalence of cancer of the large bowel in Germany is estimated at 48,677 men and women every year.4

ENDOCUFF VISION® is available in Austria, Denmark, Germany, Ireland, Norway, Spain, Sweden, Switzerland and UK.

Ends

NOTES TO EDITORS:

About ENDOCUFF VISION®

ENDOCUFF VISION® is a single-use endoscopic overtube, which fits onto the distal end of an endoscope. The size of the device is approximately 2.5cm long by 1.5cm wide (3.5cm with arms extended), and is of minimal weight.

ENDOCUFF VISION® has unique hinged arms that lie flat against the shaft of the endoscope to create a smooth, low friction surface during intubation. During extubation the arms of the device flare out to stabilise the tip of the endoscope and centre it in the lumen, providing greater control and enabling the physician to flatten the folds of the colon, leading to superior visualisation.

The device is manufactured in the UK by Boddingtons Plastics Limited, a plastics manufacturer, which currently holds the CE mark for the product.

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people.

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

ENDOCUFF VISION is a registered trademark of Arc Medical Design Ltd.

About Arc Medical Design Ltd.

Providing award-winning and innovative products worldwide, Arc Medical are leading the way in increasing Adenoma Detection Rates (ADR) and improving retrieval methods.

As a clinician driven company, Arc Medical is uniquely positioned to understand the needs of those working in the gastro-intestinal sector and strives to improve physician experience and patient outcome.

In April 2015, Norgine B.V. acquired a 70% stake in Arc Medical Design Ltd. while retaining Arc Medical Design existing management, who still own a 30% ownership stake.

Media Contacts

Isabelle Jouin : +44 (0)1895 453643
Charlotte Andrews: +44 (0)1895 453669
Follow us @norgine

Arc Medical Design Ltd:
Tas Javed: +44 (0)113 242 0131

1. The addition of a novel colonoscope device improves adenoma detection in a German screening population which may result in cost savings due to fewer cases of colorectal cancer. Abstract PMD61. ISPOR Annual Congress 2015.
2. Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 9 November 2015]
3. Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
4. Prevalence of large bowel cancer in Germany. http://eco.iarc.fr/eucan/Country.aspx?ISOCountryCd=276. [Accessed 4 November 2015]

Comments are closed.